Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
-
Assembly Biosciences prices $175 million equity financing with Gilead
-
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
-
GoPro secures $50 million term loan from Farallon Capital
-
GoPro Raises $50 Million Secured Term Loan
-
Visteon appoints Marjorie Sennett to board of directors
-
Visteon Names Marjorie Sennett to Board of Directors
-
Visteon Names Marjorie Sennett to Board of Directors
-
Form SCHEDULE 13G Liquidia Corp Filed by: Farallon Capital Partners, L.P.
-
JOINT VENTURE OF FETNER PROPERTIES, MCB REAL ESTATE AND FARALLON CAPITAL MANAGEMENT CLOSE ON $209 MILLION ACQUISITION OF 240 WILLOUGHBY STREET IN FORT GREENE, BROOKLYN
-
Form D/A Farallon Capital F5 Inve
-
Form D/A Farallon Capital F5 Inve
-
$252.5M financing secured for a 3.64M SF national industrial portfolio
-
Form SCHEDULE 13G 23andMe Holding Co. Filed by: Farallon Capital Partners, L.P.
-
At Home Group Enters Agreement to Facilitate Ownership Transition and Position Business for Long-Term Success
-
Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: Farallon Capital Partners, L.P.
-
Farallon Capital Management Releases Investor Presentation Outlining Value Creation Opportunities at T&D Holdings and the Need for Additional Independent Outside Directors
-
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form N-PX/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form N-PX/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Mar 31
-
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.
-
Pentera Secures $60M to Lead Security Validation Market Consolidation and Drive Next Phase of Growth
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Partner
-
Form D/A Farallon Capital (AM)
-
Form D/A Farallon Capital Institu
-
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G NEW YORK TIMES CO Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G Aramark Filed by: Farallon Capital Partners, L.P.
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-NT Farallon Capital Europe For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Farallon Capital Builds Over 3% Position In Japan's Astellas- FT
-
Form SCHEDULE 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
-
Bain Capital says it may withdraw tender offer proposal for Fuji Soft
-
Form SCHEDULE 13G/A AleAnna, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Forte Biosciences, Inc. Filed by: Farallon Capital Partners, L.P.

